Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.


Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?


Please Try Again {{ error }}

Send my password

An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Pre-Market Review on Biotechnology Equities -- Northwest Biotherapeutics, Titan Pharma, Ultragenyx Pharma, and Athersys


PR Newswire

NEW YORK, June 29, 2016 /PRNewswire/ --

On Tuesday, June 28, 2016, the NASDAQ Composite ended the trading session at 4,691.87, up 2.12%; the Dow Jones Industrial Average advanced 1.57%, to finish at 17,409.72; and the S&P 500 closed at 2,036.09, up 1.78%. The gains were broad based as all the sectors ended the session in positive. has initiated coverage on the following equities: Northwest Biotherapeutics Inc. (NASDAQ: NWBO), Titan Pharmaceuticals Inc. (NASDAQ: TTNP), Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), and Athersys Inc. (NASDAQ: ATHX). Learn more about these stocks by accessing their free trade alerts at:

On Tuesday, shares in Bethesda, Maryland headquartered biotechnology Company, Northwest Biotherapeutics Inc., ended the session 6.43% higher at $0.60 with a total volume of 441,611 shares traded. The stock is trading 38.97% below its 50-day moving average. Moreover, shares of Northwest Biotherapeutics have a Relative Strength Index (RSI) of 34.92. Sign up and read the free notes on NWBO at:

South San Francisco, California-based specialty pharmaceutical Company, Titan Pharmaceuticals Inc.'s stock finished Tuesday's session 1.63% higher at $5.60 with a total volume of 342,738 shares traded. The Company's shares have gained 14.29% in the past three months. The stock is trading above its 200-day moving average by 18.15%. Titan Pharmaceuticals' stock has an RSI of 42.11. The complimentary notes on TTNP can be downloaded in PDF format at:

Novato, California headquartered clinical-stage biopharmaceutical Company, Ultragenyx Pharmaceutical Inc.'s stock gained 7.34% to close the day at $50.73. The stock recorded a trading volume of 1.16 million shares, which was above its three months average volume of 624,380 shares. The stock is trading 21.36% below its 50-day moving average. Additionally, Ultragenyx Pharmaceutical's stock has an RSI of 34.71. Register for free on and access the latest research on RARE at:

On Tuesday, shares in Cleveland, Ohio headquartered biotechnology Company, Athersys Inc., ended the day 6.12% higher at $2.08 with a total volume of 592,817 shares traded. Shares of the Company traded at a PE ratio of 231.11. The Company's shares have rallied 76.27% in the past one year. The stock is trading above its 200-day moving average by 28.77%. Furthermore, shares of Athersys have an RSI of 41.95. Get free access to your trade alert on ATHX at:


Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:


Phone number:  +44 330 808 3765

Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA